Early myocardial injury in children on doxorubicin for cancer chemotherapy

Written By CCRG

A cross-sectional study in a tertiary referral centre in Kenya

Kariuki N, Kimani E, Jowi C, Wamalwa D, Suen JY, Fraser JF, Obonyo NG. BMC Cardiovasc Disord DOI 10.1186/s12872-024-03922-y

Introduction: Use of doxorubicin, an anthracycline chemotherapeutic agent has been associated with late-occurring cardiac toxicities. Detection of early-occurring cardiac effects of cancer chemotherapy is essential to prevent occurrence of adverse events including toxicity, myocardial dysfunction, and death.

Objective: To investigate the prevalence of elevated cardiac troponin T (cTnT) and associated factors of myocardial injury in children on doxorubicin cancer chemotherapy.

CCRG
Previous

Cost-effectiveness of nasal high-flow in children with acute hypoxaemic respiratory failure
Next

Median Arcuate Ligament Syndrome (MALS) in Hepato-Pancreato-Biliary Surgery